ReviewDiscover nano2026
Nanocarrier mediated microRNA delivery for oral squamous cell carcinoma a scoping review of delivery architecture preclinical efficacy and translational barriers.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor thirty years, the five-year survival rate for oral squamous cell carcinoma (OSCC) has remained below 60%. One major limitation is the absence of delivery systems that can take advantage of the molecular weaknesses unique to OSCC. MicroRNAs (miRNAs) control tumor-suppressive and carcinogenic pathways post-transcriptionally, but their therapeutic application is hindered by endosomal sequestration, low cellular uptake and quick nuclease-mediated destruction. These obstacles are addressed by nanocarrier platforms, while translational evidence unique to OSCC is dispersed.
methodsA scoping review was conducted following PRISMA-ScR guidance. PubMed/MEDLINE, Scopus, Web of Science and Google Scholar were searched from January 2014 to March 2025 using Boolean search strings combining miRNA delivery, nanocarrier platform and OSCC terminology. Original research articles and early-phase clinical trials reporting quantitative preclinical or clinical outcomes were eligible. Two independent reviewers screened records; data were extracted on nanocarrier type, miRNA cargo, biological targets, efficacy metrics, toxicity and regulatory status.
resultsSixty-one studies met eligibility criteria. Liposomes (n = 18), polymeric nanoparticles (n = 17), lipid nanoparticles (n = 10), dendrimers (n = 9) and inorganic carriers (n = 7) were the dominant platforms. Tumor-suppressive miR-34a, miR-145, miR-200c and miR-199a-3p demonstrated the most consistent preclinical efficacy, with tumor volume reductions of 38-65% in OSCC xenograft models. Stimulus-responsive systems improved intratumoral miRNA availability by limiting premature cargo release. Immunogenicity, hepatic off-target accumulation and manufacturing scale-up were the dominant translation barriers. The MRX34 phase I trial, the only completed human study, was terminated due to cytokine release syndrome.
conclusionNanocarrier-mediated miRNA delivery shows encouraging preclinical evidence in OSCC, largely from immunodeficient xenograft systems, but mechanistic heterogeneity, immunogenicity and the absence of standardized preclinical models impede clinical translation. Future development may benefit from prioritizing ionizable lipid formulations with defined immunocompatibility profiles, biomarker-stratified patient selection and orthotopic immune-competent OSCC models. Clinical trial number Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.